Alkermes Plc Stock Alpha and Beta Analysis
| ALKS Stock | USD 28.26 0.28 1.00% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Alkermes Plc. It also helps investors analyze the systematic and unsystematic risks associated with investing in Alkermes Plc over a specified time horizon. Remember, high Alkermes Plc's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Alkermes Plc's market risk premium analysis include:
Beta 1.1 | Alpha (0.14) | Risk 2.16 | Sharpe Ratio (0.06) | Expected Return (0.13) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Alkermes Plc Backtesting, Alkermes Plc Valuation, Alkermes Plc Correlation, Alkermes Plc Hype Analysis, Alkermes Plc Volatility, Alkermes Plc History and analyze Alkermes Plc Performance. Alkermes Plc Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Alkermes Plc market risk premium is the additional return an investor will receive from holding Alkermes Plc long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Alkermes Plc. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Alkermes Plc's performance over market.| α | -0.14 | β | 1.10 |
Alkermes Plc expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Alkermes Plc's Buy-and-hold return. Our buy-and-hold chart shows how Alkermes Plc performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Alkermes Plc Market Price Analysis
Market price analysis indicators help investors to evaluate how Alkermes Plc stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Alkermes Plc shares will generate the highest return on investment. By understating and applying Alkermes Plc stock market price indicators, traders can identify Alkermes Plc position entry and exit signals to maximize returns.
Alkermes Plc Return and Market Media
The median price of Alkermes Plc for the period between Sun, Oct 5, 2025 and Sat, Jan 3, 2026 is 29.72 with a coefficient of variation of 4.85. The daily time series for the period is distributed with a sample standard deviation of 1.45, arithmetic mean of 29.93, and mean deviation of 1.25. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Reed Joshua of 36656 shares of Alkermes Plc subject to Rule 16b-3 | 10/08/2025 |
2 | Disposition of 3049 shares by David Gaffin of Alkermes Plc at 34.795 subject to Rule 16b-3 | 10/31/2025 |
3 | Disposition of 5000 shares by Hopkinson Craig C. of Alkermes Plc at 19.34 subject to Rule 16b-3 | 11/03/2025 |
4 | ALKS or ILMN Which Is the Better Value Stock Right Now | 11/11/2025 |
5 | Agiloft Named a Leader in the 2025 Gartner Magic Quadrant for Contract Life Cycle Management | 11/14/2025 |
6 | Alkermes increases offer to acquire Avadel Pharmaceuticals to 22.50 per share ALKSAVDL | 11/19/2025 |
7 | Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer | 12/01/2025 |
8 | Should Strong Q3 Results and Raised 2025 Guidance Require Action From Alkermes Investors | 12/02/2025 |
9 | Disposition of 3748 shares by Hopkinson Craig C. of Alkermes Plc at 19.34 subject to Rule 16b-3 | 12/03/2025 |
10 | Are Investors Undervaluing Alkermes Right Now | 12/08/2025 |
11 | Trends and Market Growth Opportunities in the Alcohol Use Disorder Industry, 2025-2032 | 12/11/2025 |
12 | Acquisition by Wright Christopher I of 8013 shares of Alkermes Plc subject to Rule 16b-3 | 12/19/2025 |
13 | Why Analysts are Rating Alkermes a Buy | 12/22/2025 |
14 | Disposition of 4000 shares by Hopkinson Craig C. of Alkermes Plc at 28.0 subject to Rule 16b-3 | 01/02/2026 |
About Alkermes Plc Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Alkermes or other stocks. Alpha measures the amount that position in Alkermes Plc has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 | 2025 | 2026 (projected) | Days Sales Outstanding | 73.11 | 91.28 | 104.97 | 97.17 | PTB Ratio | 3.83 | 3.25 | 3.73 | 3.55 |
Alkermes Plc Upcoming Company Events
As portrayed in its financial statements, the presentation of Alkermes Plc's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Alkermes Plc's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Alkermes Plc's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Alkermes Plc. Please utilize our Beneish M Score to check the likelihood of Alkermes Plc's management manipulating its earnings.
| 15th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 15th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Alkermes Plc
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Alkermes Stock Analysis
When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.